Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 (erfonrilimab) in advanced thymic carcinoma after ICI failure
NCT04925947Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in thymic carcinoma (TC), sponsored by Weill Cornell Medicine. Started Dec 2021; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT04925947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925947.